MX2016004329A - Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. - Google Patents
Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.Info
- Publication number
- MX2016004329A MX2016004329A MX2016004329A MX2016004329A MX2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A
- Authority
- MX
- Mexico
- Prior art keywords
- benralizumab
- methods
- chronic obstructive
- obstructive pulmonary
- treating chronic
- Prior art date
Links
- 229950000321 benralizumab Drugs 0.000 title abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361891175P | 2013-10-15 | 2013-10-15 | |
| US201461970126P | 2014-03-25 | 2014-03-25 | |
| PCT/US2014/060432 WO2015057668A1 (en) | 2013-10-15 | 2014-10-14 | Methods for treating chronic obstructive pulmonary disease using benralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004329A true MX2016004329A (es) | 2016-11-10 |
Family
ID=52809872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004329A MX2016004329A (es) | 2013-10-15 | 2014-10-14 | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. |
| MX2019013468A MX2019013468A (es) | 2013-10-15 | 2016-04-04 | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013468A MX2019013468A (es) | 2013-10-15 | 2016-04-04 | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150104447A1 (OSRAM) |
| EP (2) | EP3485902A1 (OSRAM) |
| JP (3) | JP2016534996A (OSRAM) |
| KR (1) | KR20160061352A (OSRAM) |
| CN (2) | CN105636607A (OSRAM) |
| AU (2) | AU2014334563A1 (OSRAM) |
| BR (1) | BR112016008082A2 (OSRAM) |
| CA (1) | CA2925402A1 (OSRAM) |
| MX (2) | MX2016004329A (OSRAM) |
| RU (1) | RU2706729C2 (OSRAM) |
| SG (2) | SG11201601807XA (OSRAM) |
| WO (1) | WO2015057668A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160068613A1 (en) | 2013-04-29 | 2016-03-10 | Hoffmann-La Roche Inc. | Fc-receptor binding modified asymmetric antibodies and methods of use |
| MX380658B (es) | 2014-01-15 | 2025-03-11 | Hoffmann La Roche | Variantes de region fc con union mejorada de la proteina a. |
| US10479836B2 (en) | 2015-06-01 | 2019-11-19 | National University Corporation University Of Toyama | Method for treating pulmonary hypertension with interleukin-5 receptor antibody |
| CN109544378B (zh) * | 2018-10-27 | 2024-06-25 | 平安医疗健康管理股份有限公司 | 一种肺源性心脏病资质认证方法、设备及服务器 |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| MX2022006812A (es) * | 2019-12-06 | 2022-08-25 | Sanofi Biotechnology | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |
| EP3957308A1 (en) | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| CA3223191A1 (en) * | 2021-09-03 | 2023-03-09 | University Of Utah Research Foundation | Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| AU3672800A (en) * | 1999-04-09 | 2000-11-14 | Kyowa Hakko Kogyo Co. Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001060405A1 (en) * | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| ES2558689T3 (es) * | 2007-05-14 | 2016-02-08 | Medimmune, Llc | Métodos para reducir los niveles de eosinófilos |
| CN101249093A (zh) * | 2008-03-19 | 2008-08-27 | 李虎山 | 一种治疗慢性阻塞性肺部疾病的组合物 |
| PL2627673T3 (pl) * | 2010-10-15 | 2018-01-31 | Medimmune Ltd | Terapie poprawiające funkcje płuc |
| WO2012083132A2 (en) * | 2010-12-16 | 2012-06-21 | Genentech, Inc. | Diagnosis and treatments relating to th2 inhibition |
| EP2710370A4 (en) * | 2011-05-18 | 2015-01-07 | Medimmune Llc | METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS |
| CA2853858A1 (en) * | 2011-11-01 | 2013-05-10 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
| SG11201600484TA (en) * | 2013-08-12 | 2016-02-26 | Medimmune Llc | Methods for improving asthma symptoms using benralizumab |
| DK3033104T3 (da) * | 2013-08-12 | 2019-06-17 | Astrazeneca Ab | Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab |
| CN105451760A (zh) * | 2013-08-12 | 2016-03-30 | 米迪缪尼有限公司 | 使用贝那利珠单抗降低哮喘恶化率的方法 |
-
2014
- 2014-10-14 EP EP18189626.7A patent/EP3485902A1/en not_active Withdrawn
- 2014-10-14 CA CA2925402A patent/CA2925402A1/en not_active Abandoned
- 2014-10-14 JP JP2016523209A patent/JP2016534996A/ja active Pending
- 2014-10-14 KR KR1020167009675A patent/KR20160061352A/ko not_active Ceased
- 2014-10-14 MX MX2016004329A patent/MX2016004329A/es unknown
- 2014-10-14 SG SG11201601807XA patent/SG11201601807XA/en unknown
- 2014-10-14 CN CN201480056549.0A patent/CN105636607A/zh active Pending
- 2014-10-14 WO PCT/US2014/060432 patent/WO2015057668A1/en not_active Ceased
- 2014-10-14 AU AU2014334563A patent/AU2014334563A1/en not_active Abandoned
- 2014-10-14 EP EP14853201.3A patent/EP3057609A4/en not_active Withdrawn
- 2014-10-14 US US14/513,866 patent/US20150104447A1/en not_active Abandoned
- 2014-10-14 RU RU2016118425A patent/RU2706729C2/ru active
- 2014-10-14 CN CN202110508239.XA patent/CN113230399A/zh active Pending
- 2014-10-14 SG SG10201807318RA patent/SG10201807318RA/en unknown
- 2014-10-14 BR BR112016008082A patent/BR112016008082A2/pt not_active Application Discontinuation
-
2016
- 2016-04-04 MX MX2019013468A patent/MX2019013468A/es unknown
- 2016-05-31 US US15/168,711 patent/US20170107291A1/en not_active Abandoned
-
2017
- 2017-11-29 US US15/825,526 patent/US20180291108A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/422,212 patent/US20200123262A1/en not_active Abandoned
- 2019-07-18 JP JP2019132432A patent/JP6870037B2/ja active Active
-
2020
- 2020-04-02 AU AU2020202333A patent/AU2020202333A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068065A patent/JP2021107421A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019013468A (es) | 2020-02-12 |
| JP6870037B2 (ja) | 2021-05-12 |
| EP3057609A4 (en) | 2017-03-22 |
| SG10201807318RA (en) | 2018-09-27 |
| CN105636607A (zh) | 2016-06-01 |
| WO2015057668A1 (en) | 2015-04-23 |
| JP2019203009A (ja) | 2019-11-28 |
| AU2014334563A1 (en) | 2016-04-07 |
| CA2925402A1 (en) | 2015-04-23 |
| CN113230399A (zh) | 2021-08-10 |
| KR20160061352A (ko) | 2016-05-31 |
| EP3057609A1 (en) | 2016-08-24 |
| JP2021107421A (ja) | 2021-07-29 |
| US20200123262A1 (en) | 2020-04-23 |
| JP2016534996A (ja) | 2016-11-10 |
| AU2020202333A1 (en) | 2020-04-23 |
| US20170107291A1 (en) | 2017-04-20 |
| BR112016008082A2 (pt) | 2017-10-17 |
| RU2706729C2 (ru) | 2019-11-20 |
| US20180291108A1 (en) | 2018-10-11 |
| EP3485902A1 (en) | 2019-05-22 |
| RU2016118425A (ru) | 2017-11-21 |
| SG11201601807XA (en) | 2016-04-28 |
| US20150104447A1 (en) | 2015-04-16 |
| RU2016118425A3 (OSRAM) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| MX2023000079A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales. | |
| MX2016002826A (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
| PL3791896T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| PH12015501108B1 (en) | Treatment of pulmonary disease | |
| EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| MX2015017970A (es) | Metodos para tratar la poliposis nasal mediante la administracion de un antagonista de il-4r. | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| NZ710726A (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
| EA201990684A1 (ru) | Способы применения оксигенированных холестеролсульфатов (ocs) | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| MX2016001383A (es) | Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab. | |
| EA201491286A1 (ru) | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину | |
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| MX2015013066A (es) | Usos terapéuticos para anticuerpos contra vegfr1. | |
| MX351189B (es) | Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares. | |
| MX2016001384A (es) | Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab. | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| EA201792282A1 (ru) | Способы лечения заболеваний | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| EA201690445A1 (ru) | Лечение рака |